Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma

Clinical trial NCT05564338 · WITHDRAWN

Trial details

NCT number: NCT05564338
Sponsor: BeiGene
Status: WITHDRAWN
Phase: Phase 3
Study type: INTERVENTIONAL

Hepatocellular Carcinoma

Start date: 2023-06-30
Primary completion: 2027-04-30
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.